ENTRY       mmu05235                    Pathway
NAME        PD-L1 expression and PD-1 checkpoint pathway in cancer - Mus musculus (mouse)
DESCRIPTION Programmed cell death 1 (PD1) and its ligand (PDL1) are key regulatory physiological immune checkpoints that maintain self-tolerance in the organism by regulating the degree of activation of T and B  cells amongst other immune cell types. In solid tumors, the PD-1/PD-L1 inhibitory pathway can be (mis-)used to silence the immune system by increasing the expression of PD-L1 on the tumor cell surface. Up-regulation of PD-L1 is caused by activation of pro-survival pathways MAPK and PI3K/Akt as well as transcriptional factors HIF-1, STAT3 and NF-kappa B. The MAPK and PI3K signalling pathways are activated by gene mutations and growth factors. PD-L1 on tumor cells may then engage the PD-1 receptors resulting in suppression of T-cell mediated immune response. Therapeutic antibodies blocking the PD-1/PD-L1 pathway by targeting PD-L1 or PD-1 are highly effective in rescuing T cell anti-tumor effector functions.
CLASS       Human Diseases; Cancer: overview
PATHWAY_MAP mmu05235  PD-L1 expression and PD-1 checkpoint pathway in cancer
ORGANISM    Mus musculus (mouse) [GN:mmu]
GENE        15251  Hif1a; hypoxia inducible factor 1, alpha subunit [KO:K08268]
            13645  Egf; epidermal growth factor [KO:K04357]
            13649  Egfr; epidermal growth factor receptor [KO:K04361] [EC:2.7.10.1]
            15461  Hras; Harvey rat sarcoma virus oncogene [KO:K02833]
            16653  Kras; Kirsten rat sarcoma viral oncogene homolog [KO:K07827]
            18176  Nras; neuroblastoma ras oncogene [KO:K07828]
            110157  Raf1; v-raf-leukemia viral oncogene 1 [KO:K04366] [EC:2.7.11.1]
            26395  Map2k1; mitogen-activated protein kinase kinase 1 [KO:K04368] [EC:2.7.12.2]
            26396  Map2k2; mitogen-activated protein kinase kinase 2 [KO:K04369] [EC:2.7.12.2]
            26413  Mapk1; mitogen-activated protein kinase 1 [KO:K04371] [EC:2.7.11.24]
            26417  Mapk3; mitogen-activated protein kinase 3 [KO:K04371] [EC:2.7.11.24]
            14281  Fos; FBJ osteosarcoma oncogene [KO:K04379]
            16476  Jun; jun proto-oncogene [KO:K04448]
            78798  Eml4; echinoderm microtubule associated protein like 4 [KO:K15420]
            11682  Alk; anaplastic lymphoma kinase [KO:K05119] [EC:2.7.10.1]
            18709  Pik3r2; phosphoinositide-3-kinase regulatory subunit 2 [KO:K02649]
            18708  Pik3r1; phosphoinositide-3-kinase regulatory subunit 1 [KO:K02649]
            18710  Pik3r3; phosphoinositide-3-kinase regulatory subunit 3 [KO:K02649]
            18706  Pik3ca; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha [KO:K00922] [EC:2.7.1.153]
            18707  Pik3cd; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta [KO:K00922] [EC:2.7.1.153]
            74769  Pik3cb; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta [KO:K00922] [EC:2.7.1.153]
            19211  Pten; phosphatase and tensin homolog [KO:K01110] [EC:3.1.3.16 3.1.3.48 3.1.3.67]
            11651  Akt1; thymoma viral proto-oncogene 1 [KO:K04456] [EC:2.7.11.1]
            11652  Akt2; thymoma viral proto-oncogene 2 [KO:K04456] [EC:2.7.11.1]
            23797  Akt3; thymoma viral proto-oncogene 3 [KO:K04456] [EC:2.7.11.1]
            56717  Mtor; mechanistic target of rapamycin kinase [KO:K07203] [EC:2.7.11.1]
            58988  Rps6kb2; ribosomal protein S6 kinase, polypeptide 2 [KO:K04688] [EC:2.7.11.1]
            72508  Rps6kb1; ribosomal protein S6 kinase, polypeptide 1 [KO:K04688] [EC:2.7.11.1]
            12675  Chuk; conserved helix-loop-helix ubiquitous kinase [KO:K04467] [EC:2.7.11.10]
            16150  Ikbkb; inhibitor of kappaB kinase beta [KO:K07209] [EC:2.7.11.10]
            16151  Ikbkg; inhibitor of kappaB kinase gamma [KO:K07210]
            18035  Nfkbia; nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha [KO:K04734]
            18036  Nfkbib; nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, beta [KO:K02581]
            18037  Nfkbie; nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, epsilon [KO:K05872]
            18033  Nfkb1; nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 [KO:K02580]
            19697  Rela; v-rel reticuloendotheliosis viral oncogene homolog A (avian) [KO:K04735]
            15978  Ifng; interferon gamma [KO:K04687]
            15979  Ifngr1; interferon gamma receptor 1 [KO:K05132]
            15980  Ifngr2; interferon gamma receptor 2 [KO:K05133]
            16451  Jak1; Janus kinase 1 [KO:K11217] [EC:2.7.10.2]
            16452  Jak2; Janus kinase 2 [KO:K04447] [EC:2.7.10.2]
            20846  Stat1; signal transducer and activator of transcription 1 [KO:K11220]
            20848  Stat3; signal transducer and activator of transcription 3 [KO:K04692]
            24088  Tlr2; toll-like receptor 2 [KO:K10159]
            21898  Tlr4; toll-like receptor 4 [KO:K10160]
            81897  Tlr9; toll-like receptor 9 [KO:K10161]
            117149  Tirap; toll-interleukin 1 receptor (TIR) domain-containing adaptor protein [KO:K05403]
            17874  Myd88; myeloid differentiation primary response gene 88 [KO:K04729]
            22034  Traf6; TNF receptor-associated factor 6 [KO:K03175] [EC:2.3.2.27]
            18018  Nfatc1; nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1 [KO:K04446]
            18019  Nfatc2; nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 2 [KO:K17332]
            18021  Nfatc3; nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 3 [KO:K17333]
            106759  Ticam1; toll-like receptor adaptor molecule 1 [KO:K05842]
            225471  Ticam2; toll-like receptor adaptor molecule 2 [KO:K05409]
            60533  Cd274; CD274 antigen [KO:K06745]
            18566  Pdcd1; programmed cell death 1 [KO:K06744]
            15170  Ptpn6; protein tyrosine phosphatase, non-receptor type 6 [KO:K05697] [EC:3.1.3.48]
            19247  Ptpn11; protein tyrosine phosphatase, non-receptor type 11 [KO:K07293] [EC:3.1.3.48]
            381319  Batf3; basic leucine zipper transcription factor, ATF-like 3 [KO:K09034]
            53314  Batf; basic leucine zipper transcription factor, ATF-like [KO:K09034]
            74481  Batf2; basic leucine zipper transcription factor, ATF-like 2 [KO:K09034]
            12995  Csnk2a1; casein kinase 2, alpha 1 polypeptide [KO:K03097] [EC:2.7.11.1]
            13000  Csnk2a2; casein kinase 2, alpha prime polypeptide [KO:K03097] [EC:2.7.11.1]
            13001  Csnk2b; casein kinase 2, beta polypeptide [KO:K03115]
            12504  Cd4; CD4 antigen [KO:K06454]
            16818  Lck; lymphocyte protein tyrosine kinase [KO:K05856] [EC:2.7.10.2]
            12501  Cd3e; CD3 antigen, epsilon polypeptide [KO:K06451]
            12502  Cd3g; CD3 antigen, gamma polypeptide [KO:K06452]
            12503  Cd247; CD247 antigen [KO:K06453]
            12500  Cd3d; CD3 antigen, delta polypeptide [KO:K06450]
            22637  Zap70; zeta-chain (TCR) associated protein kinase [KO:K07360] [EC:2.7.10.2]
            26406  Map3k3; mitogen-activated protein kinase kinase kinase 3 [KO:K04421] [EC:2.7.11.25]
            26397  Map2k3; mitogen-activated protein kinase kinase 3 [KO:K04432] [EC:2.7.12.2]
            26399  Map2k6; mitogen-activated protein kinase kinase 6 [KO:K04433] [EC:2.7.12.2]
            26416  Mapk14; mitogen-activated protein kinase 14 [KO:K04441] [EC:2.7.11.24]
            19094  Mapk11; mitogen-activated protein kinase 11 [KO:K04441] [EC:2.7.11.24]
            29857  Mapk12; mitogen-activated protein kinase 12 [KO:K04441] [EC:2.7.11.24]
            26415  Mapk13; mitogen-activated protein kinase 13 [KO:K04441] [EC:2.7.11.24]
            16797  Lat; linker for activation of T cells [KO:K07362]
            18803  Plcg1; phospholipase C, gamma 1 [KO:K01116] [EC:3.1.4.11]
            19057  Ppp3cc; protein phosphatase 3, catalytic subunit, gamma isoform [KO:K04348] [EC:3.1.3.16]
            19055  Ppp3ca; protein phosphatase 3, catalytic subunit, alpha isoform [KO:K04348] [EC:3.1.3.16]
            19056  Ppp3cb; protein phosphatase 3, catalytic subunit, beta isoform [KO:K04348] [EC:3.1.3.16]
            19058  Ppp3r1; protein phosphatase 3, regulatory subunit B, alpha isoform (calcineurin B, type I) [KO:K06268]
            19059  Ppp3r2; protein phosphatase 3, regulatory subunit B, alpha isoform (calcineurin B, type II) [KO:K06268]
            19419  Rasgrp1; RAS guanyl releasing protein 1 [KO:K04350]
            12487  Cd28; CD28 antigen [KO:K06470]
            18761  Prkcq; protein kinase C, theta [KO:K18052] [EC:2.7.11.13]
COMPOUND    C00076  Calcium cation
            C00165  Diacylglycerol
            C01245  D-myo-Inositol 1,4,5-trisphosphate
            C05981  Phosphatidylinositol-3,4,5-trisphosphate
REFERENCE   PMID:29097600
  AUTHORS   Kythreotou A, Siddique A, Mauri FA, Bower M, Pinato DJ
  TITLE     PD-L1.
  JOURNAL   J Clin Pathol 71:189-194 (2018)
            DOI:10.1136/jclinpath-2017-204853
REFERENCE   PMID:27816403
  AUTHORS   Zhou TC, Sankin AI, Porcelli SA, Perlin DS, Schoenberg MP, Zang X
  TITLE     A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
  JOURNAL   Urol Oncol 35:14-20 (2017)
            DOI:10.1016/j.urolonc.2016.10.004
REFERENCE   PMID:29910728
  AUTHORS   Wang Y, Wang H, Yao H, Li C, Fang JY, Xu J
  TITLE     Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion.
  JOURNAL   Front Pharmacol 9:536 (2018)
            DOI:10.3389/fphar.2018.00536
REFERENCE   PMID:30646912
  AUTHORS   Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, Wu X, Ma J, Zhou M, Li X, Li Y, Li G, Xiong W, Guo C, Zeng Z
  TITLE     Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape.
  JOURNAL   Mol Cancer 18:10 (2019)
            DOI:10.1186/s12943-018-0928-4
REFERENCE   PMID:28018338
  AUTHORS   Bardhan K, Anagnostou T, Boussiotis VA
  TITLE     The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation.
  JOURNAL   Front Immunol 7:550 (2016)
            DOI:10.3389/fimmu.2016.00550
REFERENCE   PMID:30120503
  AUTHORS   Shi Y
  TITLE     Regulatory mechanisms of PD-L1 expression in cancer cells.
  JOURNAL   Cancer Immunol Immunother 67:1481-1489 (2018)
            DOI:10.1007/s00262-018-2226-9
REFERENCE   PMID:29765155
  AUTHORS   Zerdes I, Matikas A, Bergh J, Rassidakis GZ, Foukakis T
  TITLE     Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations.
  JOURNAL   Oncogene 37:4639-4661 (2018)
            DOI:10.1038/s41388-018-0303-3
REFERENCE   PMID:26681673
  AUTHORS   Chen J, Jiang CC, Jin L, Zhang XD
  TITLE     Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
  JOURNAL   Ann Oncol 27:409-16 (2016)
            DOI:10.1093/annonc/mdv615
REFERENCE   PMID:29262340
  AUTHORS   Glodde N, Holzel M
  TITLE     RAS and PD-L1: A Masters' Liaison in Cancer Immune Evasion.
  JOURNAL   Immunity 47:1007-1009 (2017)
            DOI:10.1016/j.immuni.2017.12.001
REFERENCE   PMID:25500094
  AUTHORS   Ritprajak P, Azuma M
  TITLE     Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma.
  JOURNAL   Oral Oncol 51:221-8 (2015)
            DOI:10.1016/j.oraloncology.2014.11.014
REFERENCE   PMID:23868869
  AUTHORS   Nirschl CJ, Drake CG
  TITLE     Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy.
  JOURNAL   Clin Cancer Res 19:4917-24 (2013)
            DOI:10.1158/1078-0432.CCR-12-1972
REFERENCE   PMID:30473697
  AUTHORS   Saeidi A, Zandi K, Cheok YY, Saeidi H, Wong WF, Lee CYQ, Cheong HC, Yong YK, Larsson M, Shankar EM
  TITLE     T-Cell Exhaustion in Chronic Infections: Reversing the State of Exhaustion and Reinvigorating Optimal Protective Immune Responses.
  JOURNAL   Front Immunol 9:2569 (2018)
            DOI:10.3389/fimmu.2018.02569
REFERENCE   PMID:28990585
  AUTHORS   Sharpe AH, Pauken KE
  TITLE     The diverse functions of the PD1 inhibitory pathway.
  JOURNAL   Nat Rev Immunol 18:153-167 (2018)
            DOI:10.1038/nri.2017.108
REFERENCE   PMID:27806234
  AUTHORS   Boussiotis VA
  TITLE     Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway.
  JOURNAL   N Engl J Med 375:1767-1778 (2016)
            DOI:10.1056/NEJMra1514296
REFERENCE   PMID:28881701
  AUTHORS   Arasanz H, Gato-Canas M, Zuazo M, Ibanez-Vea M, Breckpot K, Kochan G, Escors D
  TITLE     PD1 signal transduction pathways in T cells.
  JOURNAL   Oncotarget 8:51936-51945 (2017)
            DOI:10.18632/oncotarget.17232
REFERENCE   PMID:29114543
  AUTHORS   Zuazo M, Gato-Canas M, Llorente N, Ibanez-Vea M, Arasanz H, Kochan G, Escors D
  TITLE     Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy.
  JOURNAL   Ann Transl Med 5:385 (2017)
            DOI:10.21037/atm.2017.06.11
REFERENCE   PMID:23732914
  AUTHORS   Patsoukis N, Li L, Sari D, Petkova V, Boussiotis VA
  TITLE     PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2.
  JOURNAL   Mol Cell Biol 33:3091-8 (2013)
            DOI:10.1128/MCB.00319-13
REFERENCE   PMID:26162965
  AUTHORS   Chinai JM, Janakiram M, Chen F, Chen W, Kaplan M, Zang X
  TITLE     New immunotherapies targeting the PD-1 pathway.
  JOURNAL   Trends Pharmacol Sci 36:587-95 (2015)
            DOI:10.1016/j.tips.2015.06.005
REFERENCE   PMID:28242522
  AUTHORS   Ok CY, Young KH
  TITLE     Targeting the programmed death-1 pathway in lymphoid neoplasms.
  JOURNAL   Cancer Treat Rev 54:99-109 (2017)
            DOI:10.1016/j.ctrv.2017.01.009
REL_PATHWAY mmu04010  MAPK signaling pathway
            mmu04020  Calcium signaling pathway
            mmu04066  HIF-1 signaling pathway
            mmu04151  PI3K-Akt signaling pathway
            mmu04514  Cell adhesion molecules (CAMs)
            mmu04620  Toll-like receptor signaling pathway
            mmu04660  T cell receptor signaling pathway
KO_PATHWAY  ko05235
///
